Target-Based Screens & Pathways

Discovery Services

Select Service Type

In-Vitro
In-Vivo

TARGET BASED SCREENS (PROTEIN EXPRESSION)

Tubulin polymerization assayDRF/CB/TBS-01
Tubulin polymerization assay to evaluate Oncology/other areas using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  Tubulin polymerization
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Oncology/Other areas
CD marker expression in cells/fluid by flow cytometryDRF/CB/TBS-02
CD marker expression in cells/fluid by flow cytometry to evaluate Oncology/Immunology/Other.
- Cell Model
  Based on the therapeutic area under study
- End Point
  CD markers
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Oncology/Immunology/Ot her areas
Protein expression profilingDRF/CB/TBS-03
Protein expression profiling to evaluate Oncology/other areas using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  Multiplex/ ELISA
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Oncology/Other areas
Topoisomerase II assayDRF/CB/TBS-04
Topoisomerase II assay to evaluate Oncology/other areas using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  Topoisomerase II activity
- Reference Drugs
  Topoisomerase inhibitors
- Relevance
  Oncology/Other areas

TARGET BASED SCREENS (CELL SIGNALING PATHWAYS)

B cell receptorDRF/CB/TBS-01
B cell receptor to evaluate Oncology/Immunology using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  b-cell receptor expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Oncology/Immunology
cAMP/PKADRF/CB/TBS -02
cAMP/PKA to evaluate Oncology/Other areas using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  cAMP/PKA expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ Cisplatin/ Paclitaxel etc
- Relevance
  Oncology/Other areas
DNA damage/p53 responseDRF/CB/TBS -03
DNA damage/p53 response to evaluate Oncology using Human/Murine cancer cells, measuring Gamma H2Ax/ p53 expression.
- Cell Model
  Human/Murine cancer cells
- End Point
  Gamma H2Ax/ p53 expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Oncology
ER stress responseDRF/CB/TBS -04
ER stress response to evaluate Oncology/Other areas using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  ER expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Oncology/Other areas
Glucocorticoid receptorDRF/CB/TBS -05
Glucocorticoid receptor to evaluate Inflammation, metabolic homeostasis using Receptor over expressing cells.
- Cell Model
  Receptor over expressing cells
- End Point
  Glucocorticoid receptor agonist/ antagonist activity
- Reference Drugs
  information on request
- Relevance
  Inflammation, metabolic homeostasis
Heat shock responseDRF/CB/TBS -06
Heat shock response to evaluate Oncology/Other areas using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  HSP expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Oncology/Other areas
HypoxiaDRF/CB/TBS -07
Hypoxia to evaluate Cardiovascular disorders, Oncology using based on the therapeutic area under study.
- Cell Model
  Based on the therapeutic area under study
- End Point
  HIF-1 alpha expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Cardiovascular disorders, Oncology
Interleukin 4/STAT6DRF/CB/TBS-08
Interleukin 4/STAT6 to evaluate Immune disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  IL-4 expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Immune disorders
JAK/STAT (IL-6)DRF/CB/TBS-09
JAK/STAT (IL-6) to evaluate Inflammation/Immune disorders, Oncology using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  IL-6 expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Inflammation/immune disorders, Oncology
JAK/STAT (IFN-gamma)DRF/CB/TBS-10
JAK/STAT (IFN-gamma) to evaluate Inflammation/Immune disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  IFN-gamma expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Inflammation/immune disorders
JAK/STAT (Type 1 IFN)DRF/CB/TBS-11
JAK/STAT (Type 1 IFN) to evaluate Inflammation/Immune disorders, Oncology using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  IFN expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Inflammation/immune disorders, Oncology
JAK2/STAT5DRF/CB/TBS-12
JAK2/STAT5 to evaluate Oncology using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  JAK2/STAT5 expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Oncology
MAPKDRF/CB/TBS-13
MAPK to evaluate Cell proliferation using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  MAPK expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Cell proliferation
MAPK/EGFR/Ras/RafDRF/CB/TBS-14
MAPK/EGFR/RAS/RAF to study Inflammation/immune disorders, neurological disorders, Oncology using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  MAPK/EGFR/Ras/Raf expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Inflammation/immune disorders, neurological disorders, Oncology
MAPK/MEK/B-RafDRF/CB/TBS-15
MAPK/MEK/B-Raf to evaluate Oncology using Human/Murine cancer cells.
- Cell Model
  Human/Murine cancer cells
- End Point
  MAPK/MEK/B-Raf expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Oncology
NFκB (IL-1)DRF/CB/TBS-16
NFκB (IL-1) to study Oncology, cardiovascular disorders, inflammation/immune disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  IL-1 expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Oncology, cardiovascular disorders, inflammation/immune disorders
NFκB (TNF-alpha)DRF/CB/TBS-17
NFκB (TNF-alpha) to study Oncology, Cardiovascular disorders, inflammation/Immune disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  TNF-alpha expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Oncology, cardiovascular disorders, inflammation/immune disorders
Oxidative stress responseDRF/CB/TBS-18
Oxidative stress response to study Neurological disorders, immune/inflammation disorders, Oncology, Cardiovascular disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  iNOS expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Neurological disorders, immune/inflammation disorders, Oncology, cardiovascular disorders
PI3K/AKT/FOXO3DRF/CB/TBS-19
PI3K/AKT/FOXO3 to evaluate Oncology, Immune disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  PI3K/AKT/FOXO3 expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Oncology, immune disorders
PKC/Ca2+DRF/CB/TBS-20
PKC/Ca2+ to evaluate Immune disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  PKC/Ca2+ expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Immune disorders, cardiovascular disorders, neurological disorders
T cell receptorDRF/CB/TBS-21
T cell receptor to evaluate Oncology, Immune disorders using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  T cell receptor expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Oncology, Immune disorders
TGF-betaDRF/CB/TBS-22
TGF-beta to study Inflammation/immune disorders,Cardiovascular disorders, Oncology using cell model of choice based on therapeutic area.
- Cell Model
  Based on the therapeutic area under study
- End Point
  TGF-beta expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Inflammation/Immune disorders,Cardiovascular disorders, Oncology
TNF-alpha/JNKDRF/CB/TBS-23
TNF-alpha/JNK in Based on the therapeutic area under study neurological disorders, Oncology to study Inflammation/immune disorders, Immune disorders.
- Cell Model
  Based on the therapeutic area under study neurological disorders, Oncology
- End Point
  TNF-alpha/JNK expression
- Reference Drugs
  Based on the therapeutic area under study
- Relevance
  Inflammation/immune disorders, Immune disorders
Toll-like receptor (TLR4)DRF/CB/TBS-24
Toll-like receptor (TLR4) to evaluate Immune disorders using Human Monocytes (THP-1).
- Cell Model
  Human Monocytes (THP-1)
- End Point
  Percentage inhibition in levels of TLR4/ Modulation in levels of TLR4
- Reference Drugs
  Dexamethasone/ LPS
- Relevance
Wnt/Beta-cateninDRF/CB/TBS-25
Wnt/Beta-catenin to evaluate Colon cancer using Human/Murine Colon cancer cells.
- Cell Model
  Human/Murine Colon cancer cells
- End Point
  Wnt/Beta-catenin expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Colon cancer
Wnt/Beta-catenin (APC -/-)DRF/CB/TBS-26
Wnt/Beta-catenin (APC -/-) to evaluate Colon cancer using Human/Murine Colon cancer cells.
- Cell Model
  Human/Murine Colon cancer cells
- End Point
  Wnt/Beta-catenin; (APC -/-) expression
- Reference Drugs
  Cytotoxic agents such as Doxorubicin/ cisplatin/ paclitaxel etc
- Relevance
  Colon cancer

TARGET BASED SCREENS (GPCRS/NUCLEAR RECEPTORS)

Cell based GPCR Profiling services (panel available on request)DRF/CB/TBS-27
Cell based GPCR Profiling services to evaluate Multiple Therapeutic areas using GPCR over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  GPCR over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple Therapeutic areas
Nuclear Receptor profiling services (panel available on request)DRF/CB/TBS-28
Nuclear Receptor profiling services to evaluate Multiple Therapeutic areas using Nuclear Receptor over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  Nuclear Receptor over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple Therapeutic areas

TARGET BASED SCREENS (KINASES)

Kinase profiling by biochemical assays (panel of around 400 kinases available on request)DRF/CB/TBS-29
Kinase profiling by biochemical assays to evaluate Multiple Therapeutic areas using GPCR over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  GPCR over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple Therapeutic areas

MULTIPLEX ANALYSIS PANELS

Oncology panelDRF/CB/MAP-01
Oncology panel to evaluate Multiple therapeutic areas/Wellness using GPCR over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  GPCR over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness
Immunity & Inflammation panelDRF/CB/MAP-02
Immunity & Inflammation panel to evaluate Multiple therapeutic areas/Wellness using Nuclear Receptor over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  Nuclear Receptor over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness
Angiogenesis panelDRF/CB/MAP-03
Angiogenesis panel to evaluate Multiple therapeutic areas/Wellness using GPCR over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  GPCR over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness
Neurological & Neurodegenerative panelDRF/CB/MAP-04
Neurological & Neurodegenerative panel to evaluate Multiple therapeutic areas/Wellness using Nuclear Receptor over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  Nuclear Receptor over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness
Cardiovascular panelDRF/CB/MAP-05
Cardiovascular panel to evaluate Multiple therapeutic areas/Wellness using GPCR over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  GPCR over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness
Metabolic panelDRF/CB/MAP-06
Metabolic panel to evaluate Multiple therapeutic areas/Wellness using Nuclear Receptor over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  Nuclear Receptor over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness
Organ health panel (liver, kidney, heart, muscle, bone)DRF/CB/MAP-07
Organ health panel (liver, kidney, heart, muscle, bone) to evaluate Multiple therapeutic areas/Wellness using GPCR over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  GPCR over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness
Obesity panelDRF/CB/MAP-08
Obesity panel to evaluate Multiple therapeutic areas/Wellness using Nuclear Receptor over-expressing cell lines, measuring Agonist/ antagonist activity.
- Cell Model
  Nuclear Receptor over-expressing cell lines
- End Point
  Agonist/ antagonist activity
- Reference Drugs
  Based on the selected receptor
- Relevance
  Multiple therapeutic areas/Wellness

Target-Based Screens & Pathways

Discovery Services

Select Service Type

TARGET BASED SCREENS (PROTEIN EXPRESSION)

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

TARGET BASED SCREENS (CELL SIGNALING PATHWAYS)

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs

Relevance

Cell Model

End Point

Reference Drugs